• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lyra Therapeutics closes $100.5M private placement

April 13, 2022 By Sean Whooley

Lyra Therapeutics LYR-210
LYR-210 is an investigational product designed to provide six months of anti-inflammatory treatment from a single in-office administration
(Image from Lyra Therapeutics)

Lyra Therapeutics (Nasdaq:LYRA) announced today that it closed its previously announced private placement worth $100.5 million.

The company announced last week that, in the private placement, investors had the option in the private placement to purchase either shares of Lyra’s common stock at $4.22 per share or, in lieu thereof, pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share at a purchase price of $4.219 per share (equating to $4.22 per share).

Under the agreement, certain investors agreed to purchase an aggregate of more than 18.8 million shares of common stock at the $4.22 per share purchase price. Certain investors also agreed to purchase pre-funded warrants to purchase an aggregate of 5 million shares of common stock at the same price.

“This significant financing is an important indication of investor enthusiasm for Lyra’s product candidates and management team,” Lyra Therapeutics Executive Chair Dr. Harlan W. Waksal said in a news release. “We are now positioned to further build on a track record of success, addressing the unmet need of millions of [chronic rhinosinusitis] patients and the resulting global commercial opportunity.”

New investors, including funds affiliated with Venrock Healthcare Capital Partners, funds managed by Nantahala Capital Management, LLC and Samsara BioCapital, as well as existing investors, such as funds affiliated with Perceptive Advisors, North Bridge Venture Partners and Pura Vida Investments, all participated.

Watertown, Massachusetts-based Lyra Therapeutics — which develops the XTreo platform designed to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — said that proceeds, combined with existing cash and expected milestone payments, support the extension of cash runway into mid-2024.

Proceeds will also support Lyra’s ongoing clinical development of its LYR-210 and LYR-220 therapeutics and be used for working capital and general corporate purposes as well.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Respiratory Tagged With: Lyra Therapeutics

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS